Limited gene expression variation in human embryonic stem cell and induced pluripotent stem cell-derived endothelial cells

Autor: White, MP, Rufaihah, AJ, Liu, L, Ghebremariam, YT, Ivey, KN, Cooke, JP, Srivastava, D

Publikováno v: Stem cells (Dayton, Ohio), vol 31, iss 1
White, MP; Rufaihah, AJ; Liu, L; Ghebremariam, YT; Ivey, KN; Cooke, JP; et al.(2013). Limited gene expression variation in human embryonic stem cell and induced pluripotent stem cell-derived endothelial cells. Stem Cells, 31(1), 92-103. doi: 10.1002/stem.1267. UCSF: Retrieved from: http://www.escholarship.org/uc/item/46j2f46w

Recent evidence suggests human embryonic stem cell (hESC) and induced pluripotent stem (iPS) cell lines have differences in their epigenetic marks and transcriptomes, yet the impact of these differences on subsequent terminally differentiated cells i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::4127b947f1353a73f154bea156bc25c9
https://escholarship.org/uc/item/46j2f46w

Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis.

Autor: Ghebremariam YT; Department of Cardiovascular Sciences, Houston Methodist Research Institute, 6670 Bertner Ave, R10-111, Houston, TX, 77030, USA. ytghebremariam@tmhs.org.; Department of Cardiothoracic Surgery, Weill Cornell Medical College of Cornell University, New York, NY, USA. ytghebremariam@tmhs.org., Cooke JP; Department of Cardiovascular Sciences, Houston Methodist Research Institute, 6670 Bertner Ave, R10-211, Houston, TX, 77030, USA. jpcooke@tmhs.org., Gerhart W; Altitude Pharmaceuticals, Inc, San Diego, CA, USA. wgerhart@altitudepharma.com., Griego C; Lovelace Respiratory Research Institute, Albuquerque, NM, USA. cgriego@lrri.org., Brower JB; Lovelace Respiratory Research Institute, Albuquerque, NM, USA. jbrower@lrri.org., Doyle-Eisele M; Lovelace Respiratory Research Institute, Albuquerque, NM, USA. mdoyle@lrri.org., Moeller BC; Lovelace Respiratory Research Institute, Albuquerque, NM, USA. bmoeller@lrri.org., Zhou Q; Department of Respiratory Medicine, Peking University Third Hospital, Beijing, China. zhouqingtaobysy@sina.com., Ho L; Division of Pulmonary Medicine, School of Medicine, Stanford University, Stanford, CA, USA. laho@uw.edu., de Andrade J; Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. joao@uab.edu., Raghu G; Division of Pulmonary and Critical Care Medicine, Center for Interstitial Lung Disease (ILD), University of Washington, Seattle, WA, USA. graghu@uw.edu., Peterson L; Center for Biostatistics, Houston Methodist Research Institute, Houston, TX, USA. LEPeterson@tmhs.org., Rivera A; Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston, TX, USA. alrivera@tmhs.org., Rosen GD; Division of Pulmonary Medicine, School of Medicine, Stanford University, Stanford, CA, USA. gdrosen2@gmail.com.

Publikováno v: Journal of translational medicine [J Transl Med] 2015 Aug 01; Vol. 13, pp. 249. Date of Electronic Publication: 2015 Aug 01.

Endothelium-Derived Nitric Oxide as an Antiatherogenic Mechanism: Implications for Therapy.

Autor: Sukhovershin RA; Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, Texas., Yepuri G; Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, Texas., Ghebremariam YT; Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, Texas.

Publikováno v: Methodist DeBakey cardiovascular journal [Methodist Debakey Cardiovasc J] 2015 Jul-Sep; Vol. 11 (3), pp. 166-71.

Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population.

Autor: Shah NH; Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, CA, United States of America., LePendu P; Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, CA, United States of America., Bauer-Mehren A; Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, CA, United States of America., Ghebremariam YT; Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States of America., Iyer SV; Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, CA, United States of America., Marcus J; Practice Fusion, Inc., San Francisco, CA, United States of America., Nead KT; Divisions of Cardiovascular Medicine and Vascular Surgery, Stanford University, Stanford, CA, United States of America., Cooke JP; Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, United States of America., Leeper NJ; Divisions of Cardiovascular Medicine and Vascular Surgery, Stanford University, Stanford, CA, United States of America.

Publikováno v: PloS one [PLoS One] 2015 Jun 10; Vol. 10 (6), pp. e0124653. Date of Electronic Publication: 2015 Jun 10 (Print Publication: 2015).

A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxide.

Autor: Ghebremariam YT; Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, Texas (Y.T.G., J.P.C.); and SPARK Translational Research Program, Stanford University, School of Medicine, Stanford, California (D.A.E.)., Erlanson DA, Cooke JP

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2014 Jan; Vol. 348 (1), pp. 69-76. Date of Electronic Publication: 2013 Oct 17.